Shaily Engineering Plastics Ltd Q1 FY26 Earnings Analysis

- FY '26 pen sales target: 30-35 million units, approximately 70% growth over previous year - Revenue growth in Healthcare segment: 53% YoY in FY '25, expected to contribute ~30% of total revenues in next few years - Own IP-led insulin pens expected to grow at 20-30% CAGR over next 2 years - Anticipated 77% growth in pen sales driven by IP-led pen platform, especially non-insulin products - Capacity expansion: Adding 40-50 million pens capacity in next 18-24 months, reaching total of 80-90 million pens capacity - New product launches expected, including teriparatide in FY '26 with 2 customers planned - Other segments like Consumer and Industrial expected to grow steadily, with Consumer segment growing 17% YoY in FY '25 - Potential medium to large capex in Consumer electronics in next 1-2 years based on customer agreements

- Shaily Engineering Plastics expects strong growth in revenues and margins year-on-year rather than quarter-on-quarter, with improving EBITDA margins aimed through executing current plans. - FY '25 saw EBITDA margin expand by 350 bps to 22.7%, PAT margin increased by 290 bps to 11.8%, reflecting strong profitability growth. - Growth in healthcare segment (primarily pen injectors and auto-injectors) is a key driver, with 53% revenue growth in FY '25 and anticipated to comprise ~30% of revenues in coming years. - Pen sales are expected to grow 70-77% in FY '26, with total device volumes around 30-35 million units, further supporting revenue gains. - Expansion capex of ~INR150 crores planned to increase pen manufacturing capacity by 40-50 million units over 18-24 months, underpinning future volume growth. - Profitability is expected to improve with better asset turns (1.5x to 2x) and higher utilization rates over the next 2-3 years. - No specific EPS guidance provided, but sustained growth and margin expansion suggest positive future earnings trajectory.

- Current capex for FY '26 is approximately INR150 crores focused primarily on Pharma segment capacity expansion. - Planned addition of 40 million to 50 million pen manufacturing capacity over the next 18-24 months. - Post this expansion, total pen capacity expected to be in the range of 80 to 90 million pens. - Further capacity increase beyond 90 million pens will depend on firm customer commitments or purchase orders. - Total Pharma gross block after this capex expected to be around INR370 to INR375 crores. - No immediate land acquisition planned; expansion likely near existing facilities. - Additional medium to large capex possible in Consumer Electronics in the next 1-2 years if business plans with customers materialize. - Capex investments are made gradually and are aligned with committed volumes from customers to minimize risk.

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company discusses capital expenditure plans, notably INR150 crores capex for pharma segment expansion (pen manufacturing capacity increase by 40-50 million pens). - Investments are described as being funded based on firm commitments from customers rather than through advances or external funding. - Debt-to-equity ratio as of March 31, 2025, stands at 0.4x, with long-term debt-to-equity at 0.07x, indicating moderate leverage but no mention of new debt raise. - Customer advances appear in current liabilities but are not linked to capex advances. - The management highlights disciplined capital use and focuses on organic capacity expansion aligned with firm orders. - No statements suggest immediate plans to raise equity or new debt as of May 2025.

- Shaily Engineering Plastics is expanding pen manufacturing capacity by 40-50 million pens over 18-24 months, targeting a total capacity of 80-90 million pens. - Capex for this expansion is about INR150 crores, with additional investments expected for lab and support facilities. - Further capacity increases beyond 90 million pens will depend on firm customer commitments and purchase orders. - The company has signed 8 contracts with different customers for pen or auto injectors, primarily for GLP-1 and other therapies. - For Tirzepatide (Tirze) exhibit supplies, the company expects about 2 customers launching in FY '26. - Incremental pen/autoinjector sales of 12-15 million units targeted in FY '26 are spread across 3-4 customers with no single customer approval yet. - Discussions ongoing with customers for volume and capacity commitments for the next 3-5 years. - No explicit total order book value shared; capacity expansion is tied to customer firm orders.